Cryoport Q2 revenue up 14% to $45.5M; cell & gene therapy revenue +33%; reaffirms FY25 guidance

Cryoport, Inc.

2025-Q2 EPS reported $1.78 revenue$86,494,000

Net income of $105.2M includes $117.4M gain from CRYOPDP divestiture; adjusted EBITDA improved to -$0.9M vs -$5.6M a year ago.
Life Sciences Services revenue grew 21% to $24.4M (54% of total); BioStorage/BioServices up 28%.
Commercial cell & gene therapy revenue rose 33% to $8.7M; supported 18 commercial therapies and 728 global trials.
Closed strategic partnership with DHL and divestiture of CRYOPDP on June 11, 2025; cash & investments $426M.
Reaffirmed FY2025 revenue guidance of $165M–$172M, representing 5%-10% YoY growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.